Dr. Joseph Maly
Claim this profileNorton Cancer Institute
Studies Lymphoma
Studies Leukemia
9 reported clinical trials
19 drugs studied
Area of expertise
1Lymphoma
MYC positive
BCL6 positive
BCL2 positive
2Leukemia
Affiliated Hospitals
Clinical Trials Joseph Maly is currently running
AB-101 + Immunotherapy
for Non-Hodgkin's Lymphoma
AB-101 is an off-the shelf, allogeneic cell product made of "natural killer" cells, also called NK cells. White blood cells are part of the immune system and NK cells are a type of white blood cell that are known to kill cancer cells. This clinical trial will enroll patients with relapsed/refractory non-Hodgkin lymphoma of B-cell origin and is conducted in two phases. The primary objectives of Phase 1 are as follows: 1) to evaluate the safety of AB-101 given alone or in combination with rituximab (including the DLBCL specific cohort) or in combination with bendamustine and rituximab; 2) to evaluate the potential clinical activity of AB-101 when given in combination with rituximab or in combination with bendamustine and rituximab (combination cohorts only); and 3) to identify the recommended Phase 2 dose (RP2D). The primary objective of Phase 2 is to determine whether AB-101 in combination with rituximab or in combination with bendamustine and rituximab has anti-cancer activity in patients. Patients will be assigned to receive either AB-101 alone as monotherapy, in combination with rituximab (including DLBCL specific cohort) or in combination with bendamustine and rituximab. All patients will receive at least 1 treatment cycle of AB-101, followed by scheduled assessments of overall health and tumor response. Patients receiving AB-101 in combination with rituximab may receive up to 3 additional cycles of treatment. Patients receiving AB-101 in combination with bendamustine and rituximab may receive up to 5 additional cycles of treatment. Patients enrolled into the DLBCL specific cohort receiving AB-101 in combination with rituximab may receive up to 3 cycles of treatment.
Recruiting1 award Phase 1 & 24 criteria
REGN5458
for Multiple Myeloma
The main purpose of this study is to learn about the safety of REGN5458 and to find out what is the best dose of REGN5458 to give to patients with multiple myeloma. An additional purpose is to look for any signs that REGN5458 can treat cancer. The study is looking at several other research questions, including: * Side effects that may be experienced by people receiving REGN5458 * How REGN5458 works in the body * How much REGN5458 is present in the blood * How REGN5458 may work to treat cancer
Recruiting1 award Phase 1 & 2
More about Joseph Maly
Clinical Trial Related3 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Joseph Maly has experience with
- Rituximab
- AB-101
- Nivolumab
- Docetaxel
- Loncastuximab Tesirine
- ONO-7475
Breakdown of trials Joseph Maly has run
Lymphoma
Leukemia
Acute Myeloid Leukemia
Non-Hodgkin's Lymphoma
Prostate Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Joseph Maly specialize in?
Joseph Maly focuses on Lymphoma and Leukemia. In particular, much of their work with Lymphoma has involved MYC positive patients, or patients who are BCL6 positive.
Is Joseph Maly currently recruiting for clinical trials?
Yes, Joseph Maly is currently recruiting for 3 clinical trials in Louisville Kentucky. If you're interested in participating, you should apply.
Are there any treatments that Joseph Maly has studied deeply?
Yes, Joseph Maly has studied treatments such as Rituximab, AB-101, Nivolumab.
What is the best way to schedule an appointment with Joseph Maly?
Apply for one of the trials that Joseph Maly is conducting.
What is the office address of Joseph Maly?
The office of Joseph Maly is located at: Norton Cancer Institute, Louisville, Kentucky 40241 United States. This is the address for their practice at the Norton Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.